Straits Times Index
3,338.57 +5.77 (+0.17%) S&P 500
5,454.08 -6.40 (-0.12%) Dow
39,100.95 -17.91 (-0.05%) Nasdaq
17,749.06 +16.45 (+0.09%) Bitcoin USD
62,769.72 +1,272.64 (+2.07%) CMC Crypto 200
1,301.98 -0.09 (-0.01%)
AMRX Dec 2024 2.500 call
| Previous close | 4.7500 |
| Open | 4.7500 |
| Bid | 1.8000 |
| Ask | 6.0000 |
| Strike | 2.50 |
| Expiry date | 2024-12-20 |
| Day's range | 4.7500 - 4.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 27 |
- Business Wire
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
PISCATAWAY, N.J., July 01, 2024--Kashiv BioSciences, LLC ("Kashiv" or the "Company") today announced that it has entered into an exclusive licensing agreement for ADL018, a proposed biosimilar to omalizumab referencing XOLAIR®, with Amneal Pharmaceuticals, Inc. ("Amneal") for the United States.
Business WireAmneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
BRIDGEWATER, N.J., July 01, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced the addition of omalizumab, referencing XOLAIR®, to its biosimilar pipeline.
Business WireAmneal Releases 2023 Environmental, Social and Governance Report
BRIDGEWATER, N.J., June 28, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced the release of its fourth (2023) Environmental, Social and Governance (ESG) Report. This 2023 report provides a look at our progress against our core ESG priorities, including our commitment to embedding sustainability across our business; human capital management, including well-being, inclusion and belonging efforts; philanthropic partnerships with health-related non-profit
